Last year, pharmaceutical giant AbbVie (NYSE: ABBV) lost patent exclusivity for its biggest cash cow, immunology medicine ...

AbbVie (ABBV) reports Q3 earnings Wednesday. The acquisition of Aliada Therapeutics may boost its Alzheimer's portfolio and ...

AbbVie stock popped Wednesday after the pharma behemoth's new king in immunology finally outpaced its grandfather drug, ...

The chart below ... company's potential revenue growth is crucial. In the case of AbbVie, the consensus sales estimate of $14.87 billion for the current quarter points to a year-over-year change ...

Most pharmaceutical businesses are slow-moving by nature due to the lengthy amount of time it takes to develop a new medicine ...

At the start of 2023, U.S. patent exclusivity expired for the blockbuster drug Humira, AbbVie's chief cash cow. During the 20 ...

AbbVie (ABBV) shares snapped eight consecutive sessions of losses as the stock closed up XYZ% at $XYZ. The North ...

Real-time index price for TSX Buyback Index (TXBB), along with buy or sell indicators, analysis, charts, historical ...

Emraclidine was expected to be a blockbuster drug for AbbVie, and this development didn’t sit well with investors.

For instance, the price of AbbVie Inc. (NYSE:ABBV) stock is up an impressive 125% over the last five years. It's down 2. ... report on AbbVie's earnings, revenue and cash flow is a great place ...

Even if emraclidine is not a complete write-off, this sets back AbbVie's muscarinic pipeline by at least several years, ...